TargetMol

Lirequinil

Product Code:
 
TAR-T27838
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27838-1mg1mg£199.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27838-5mg5mg£392.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27838-10mg10mg£552.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27838-25mg25mg£841.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27838-50mg50mg£1,099.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27838-100mg100mg£1,476.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27838-500mg500mg£2,874.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Lirequinil is a GABA receptor agonist.
CAS:
143943-73-1
Formula:
C26H25ClN2O3
Molecular Weight:
448.95
Pathway:
Neuroscience|Membrane transporter/Ion channel
Purity:
0.98
SMILES:
CCO[C@H]1CCN(C1)C(=O)c1cc(-c2ccccc2)c(=O)n2CCc3ccc(Cl)cc3-c12
Target:
GABA Receptor

References

1. Dingemanse J, Pedrazzetti E, van Giersbergen PL. Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjects. Clin Neuropharmacol. 2001 Mar-Apr;24(2):82-90. PubMed PMID: 11307042. 2. Dingemanse J, Bury M, Hussain Y, van Giersbergen P. Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects. Drug Metab Dispos. 2000 Dec;28(12):1411-6. PubMed PMID: 11095577. 3. Dingemanse J, Bury M, Bock J, Joubert P. Comparative pharmacodynamics of Ro 41-3696, a new hypnotic, and zolpidem after night-time administration to healthy subjects. Psychopharmacology (Berl). 1995 Nov;122(2):169-74. PubMed PMID: 8848532. 4. Dingemanse J, Bury M, Roncari G, Zell M, Gieschke R, Gaillard AW, Odink J, van Brummelen P. Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnotic. J Clin Pharmacol. 1995 Aug;35(8):821-9. PubMed PMID: 8522640.